A Randomized Split Scar Study of Suture Safe Treatment of Surgical Wounds to Minimize Scaring

NCT ID: NCT02620475

Last Updated: 2015-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2017-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the effect SutureSafe dressings have on reducing scarring from an incision following an elective abdominoplasty (tummy tuck) procedure. The scar will be evaluated using subjective clinical assessment criteria. Each participant in the study will serve as a control and experiential study, since have of the incision will be treated with the gold standard of care and the other half with SutureSafe dressings.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients of Dr. Nick Carr's who have elected to undergo an abdominoplasty (tummy tuck) procedure and have a fitzpatrick skin type of IV-VI will be offered participation in the study.

A full tummy tuck requires a horizontally-oriented incision in the area between the pubic hairline and belly button. The shape and length of the incision will be determined by the amount of excess skin. The excess skin is trimmed and the remaining skin is sutured together. A natural part of the healing process includes the body producing a fluid. The body is also able to reabsorb some fluid, but in the beginning there is more than the body can handle. Drains are inserted for one week post-operative to help remove that fluid. The usual standard of wound treatment to prevent scarring is to cover the incision with a self adhesive gauze type dressing (Mepore) covered by paper tape. The tape will be replaced at one-week post-operative and will be removed at two-weeks post-operative when the incision has fully healed. At this point the tape will then be replaced with a silicone strip for three additional months. In addition to the dressings the patient wearing a pressure garment for 1 month post-operative.

Patients who choose to be in the study, will have one half of the incision treated with the standard of care (explained in the previous paragraph) and the other side will be treated with SutureSafe dressings. Based on the Canadian medical device classification system, SutureSafe bandages are considered a class I device (which is the lowest risk category). The same process of wound care will be followed as outlined above, half of the incision will be treated with Mepore and paper tape, the other half of the incision will be treated with self-adhesive SutureSafe dressings. Both sides of the incisions will be replaced at one-week post-operative and will be removed at two-weeks post-operative when the incision has fully healed. At this point the tape will be replaced with a silicone strip and the SutureSafe bandages will be reapplied for three additional months.

The scar will be assessed at 3 months, 6 months and 1 year post-operative by observer Baillie Redfern. The clinical assessment of the scar will be performed using the Vancouver Scar Score criteria.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Scars

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gold standard of care

The usual gold standard of wound treatment to prevent scarring is to cover the incision with a self adhesive gauze type dressing (Mepore) covered by paper tape.

Group Type ACTIVE_COMPARATOR

SutureSafe

Intervention Type DEVICE

SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.

SutureSafe dressings

SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.

Group Type EXPERIMENTAL

SutureSafe

Intervention Type DEVICE

SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SutureSafe

SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years old and older
* Have undergone an abdominoplasty procedure by Dr. Nick Carr
* Have fitzpatrick skin type IV-VI
* Be willing and able to return for all study follow-up procedures
* Have not participated in any other investigational or invasive clinical trial within the last 30 days, and will not participate in any other investigational or invasive clinical trial during this study; and
* Have been informed of the nature of the study, agreeing to its requirements, and have signed the informed consent approved by the Research Ethics Board.

Exclusion Criteria

* Are unable to meet the treatment and follow up protocol requirements.
* Less than 18 years of ageCo-morbidity that reduces life expectancy to less than 12 months
* Cannot use any other methods (i.e. parmaceuditcal, natural, homeopathic) medications or devices for scar treatment.
* In the opinion of the Investigator, any medical condition that makes the subject unsuitable for inclusion in the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of British Columbia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nick Carr, B.Sc. MD

Role: PRINCIPAL_INVESTIGATOR

The University of British Columbia

Baillie L Redfern, B.Sc., M.Sc

Role: STUDY_DIRECTOR

The University of British Columbia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Skin Works

Vancouver, British Columbia, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Baillie L Redfern, B.Sc., M.Sc

Role: CONTACT

6043622501

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nick Carr, B.Sc. MD

Role: primary

(604) 737-7100

Baillie Redfern, B.Sc. M.Sc

Role: backup

604-362-2501

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H15-02683

Identifier Type: -

Identifier Source: org_study_id